<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972903</url>
  </required_header>
  <id_info>
    <org_study_id>C20-17</org_study_id>
    <nct_id>NCT04972903</nct_id>
  </id_info>
  <brief_title>Impact of Malnutrition on Pharmacokinetic or Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children</brief_title>
  <acronym>TB-Speed TB-PK</acronym>
  <official_title>Impact of Malnutrition on Pharmacokinetic or Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Agency for Research on AIDS and Viral Hepatitis (ANRS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV&#xD;
      and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin,&#xD;
      isoniazid, pyrazinamide, and ethambutol in TB-HIV co-infected children in Uganda and Zambia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberculosis can worsen malnutrition and in turn malnutrition increases the risk of TB. HIV&#xD;
      infection is prevalent in children with TB and SAM and is often associated with poor outcomes&#xD;
      when present. TB alone is the leading cause of death of among HIV-infected children worldwide&#xD;
      accounting for a third of all the death in this group.&#xD;
&#xD;
      In 2010, the WHO recommended increased dose for rifampicin (+50%), isoniazid (+100%), and&#xD;
      pyrazinamide (+33%) based on PK data showing that plasma drug concentrations in children&#xD;
      using standard adult dosages did not reach target levels. In children that are TB/HIV&#xD;
      co-infected, drug-drug interactions between anti-TB drugs and antiretroviral drugs are of&#xD;
      concern.&#xD;
&#xD;
      The investigators hypothesize that HIV-infection and SAM, each one on its own, may have an&#xD;
      impact on TB drugs concentrations. Furthermore, SAM is frequent in children with HIV, and may&#xD;
      affect the metabolism of anti-TB drugs and consequently result in low serum concentration.&#xD;
&#xD;
      TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV&#xD;
      and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin,&#xD;
      isoniazid, pyrazinamide, and ethambutol in TB-HIV co-infected children. It will be&#xD;
      implemented in Uganda and Zambia. Children will also be enrolled from routine care for TB&#xD;
      outside of the TB- Speed HIV and TB-Speed SAM studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of SAM on Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB</measure>
    <time_frame>6 months</time_frame>
    <description>Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol peak concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of SAM on minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB</measure>
    <time_frame>6 months</time_frame>
    <description>Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol minimum concentration (Cmin or C trough)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of SAM on Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB</measure>
    <time_frame>6 months</time_frame>
    <description>Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol exposure (Area Under the Curve - AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of HIV-infection and antiretroviral treatment on Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM</measure>
    <time_frame>6 months</time_frame>
    <description>Cmax of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol in children with HIV infection on or off ART and children without HIV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of HIV-infection and antiretroviral treatment on Minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM</measure>
    <time_frame>6 months</time_frame>
    <description>Cmin of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol in children with HIV infection on or off ART and children without HIV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of HIV-infection and antiretroviral treatment on Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM</measure>
    <time_frame>6 months</time_frame>
    <description>AUC of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol in children with HIV infection on or off ART and children without HIV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO-based dosages will achieve rifampicin, isoniazid, pyrazinamide, and ethambutol drug concentrations above the target therapeutic concentrations in HIV-TB co-infected children with and without SAM</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of children with AUC24 and Cmax above the recommended threshold for Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on CL/F of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB</measure>
    <time_frame>6 months</time_frame>
    <description>CL/F(Apparent total clearance of the drug from plasma) after oral administration of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on V/F of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB</measure>
    <time_frame>6 months</time_frame>
    <description>V/F (Apparent volume of distribution after administration) after oral administration of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on Ka of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB</measure>
    <time_frame>6 months</time_frame>
    <description>Ka (Absorption rate constant) after oral administration of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between all-cause mortality in children with TB and SAM, and Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.</measure>
    <time_frame>6 months</time_frame>
    <description>Define the best Cmax plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol for treatment sucess.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between all-cause mortality in children with TB and SAM, and the minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.</measure>
    <time_frame>6 months</time_frame>
    <description>Define the best Cmin plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol for treatment sucess.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between all-cause mortality in children with TB and SAM, and Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.</measure>
    <time_frame>6 months</time_frame>
    <description>Define the best AUC plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol for treatment sucess.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rifampicin protein binding in relation with malnutrition and albuminemia</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of protein bound rifampicin in children with SAM and association with albuminemia</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Pulmonary</condition>
  <arm_group>
    <arm_group_label>Group 1.HIV+/SAM+</arm_group_label>
    <description>Group 1. HIV-infected with SAM (WHZ&lt;-3SD or edematous malnutrition or MUAC &lt;115) (HIV+/SAM+)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2. HIV+/SAM-</arm_group_label>
    <description>Group 2. HIV-infected without SAM (none of the 3 criteria above) (HIV+/SAM-)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3. HIV-/SAM+</arm_group_label>
    <description>Group 3. HIV-negative with SAM (WHZ&lt;-3SD or edematous malnutrition or MUAC &lt;115) (HIV-/SAM+)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4. HIV-/SAM-</arm_group_label>
    <description>Group 4. HIV-negative without SAM (none of the 3 criteria above) (HIV-/SAM-)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Intensive PK of rifampicin, isoniazid, pyrazinamide, and ethambutol will be performed&#xD;
        between 2 to 4 weeks of TB treatment in the following 4 groups of children receiving&#xD;
        first-line anti-TB treatment:&#xD;
&#xD;
          -  Group (Gr) 1. HIV-infected with SAM (WHZ&lt;-3SD or edematous malnutrition or MUAC &lt;115)&#xD;
             (HIV+/SAM+)&#xD;
&#xD;
          -  Gr2. HIV-infected without SAM (none of the 3 criteria above) (HIV+/SAM-)&#xD;
&#xD;
          -  Gr3. HIV-negative with SAM (WHZ&lt;-3SD or edematous malnutrition or MUAC &lt;115)&#xD;
             (HIV-/SAM+)&#xD;
&#xD;
          -  Gr4. HIV-negative without SAM (none of the 3 criteria above) (HIV-/SAM-)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Gr1. HIV-infected children with SAM&#xD;
&#xD;
               -  Age 6 months to 5 years&#xD;
&#xD;
               -  Diagnosed with TB and first line TB treatment to be initiated or started less&#xD;
                  than 4 weeks prior to inclusion&#xD;
&#xD;
               -  HIV-infection&#xD;
&#xD;
               -  SAM as defined by WHO at the time of starting TB treatment&#xD;
&#xD;
               -  Weight-for-height z-score (WHZ) &lt; -3 SD,&#xD;
&#xD;
               -  OR MUAC &lt;11.5 cm or&#xD;
&#xD;
               -  OR presence of bilateral pitting oedema of nutritional origin&#xD;
&#xD;
               -  Ability to take drugs orally during the planned PK day&#xD;
&#xD;
               -  Signed informed consent from parents or guardian&#xD;
&#xD;
          -  Gr2. HIV-infected children without SAM&#xD;
&#xD;
               -  Age 6 months to 5 years&#xD;
&#xD;
               -  Diagnosed with TB and first line TB treatment to be initiated or started less&#xD;
                  than 4 weeks prior to inclusion&#xD;
&#xD;
               -  HIV-infection&#xD;
&#xD;
               -  Absence of SAM as defined by WHO at the time of starting TB treatment&#xD;
&#xD;
               -  Weight-for-height z-score (WHZ) &gt; -3 SD,&#xD;
&#xD;
               -  AND MUAC &gt;11.5 cm or&#xD;
&#xD;
               -  AND absence of bilateral pitting oedema of nutritional origin&#xD;
&#xD;
               -  Ability to take drugs orally during the planned PK day&#xD;
&#xD;
               -  Signed informed consent from parents or guardian&#xD;
&#xD;
          -  Gr3. HIV-negative children with SAM&#xD;
&#xD;
               -  Age 6 months to 5 years&#xD;
&#xD;
               -  Diagnosed with TB and first line TB treatment to be initiated or started less&#xD;
                  than 4 weeks prior to inclusion&#xD;
&#xD;
               -  HIV-negative&#xD;
&#xD;
               -  SAM as defined by WHO at the time of starting TB treatment&#xD;
&#xD;
               -  Weight-for-height z-score (WHZ) &lt; -3 SD,&#xD;
&#xD;
               -  OR MUAC &lt;11.5 cm or&#xD;
&#xD;
               -  OR presence of bilateral pitting oedema of nutritional origin&#xD;
&#xD;
               -  Ability to take drugs orally during the planned PK day&#xD;
&#xD;
               -  Signed informed consent from parents or guardian&#xD;
&#xD;
          -  Gr4. HIV-negative children without SAM&#xD;
&#xD;
               -  Age 6 months to 5 years&#xD;
&#xD;
               -  Diagnosed with TB and first line TB treatment to be initiated or started less&#xD;
                  than 4 weeks prior to inclusion&#xD;
&#xD;
               -  HIV-negative&#xD;
&#xD;
               -  Absence of SAM as defined by WHO at the time of starting TB treatment&#xD;
&#xD;
               -  Weight-for-height z-score (WHZ) &gt; -3 SD,&#xD;
&#xD;
               -  AND MUAC &gt;11.5 cm or&#xD;
&#xD;
               -  AND absence of bilateral pitting oedema of nutritional origin&#xD;
&#xD;
               -  Ability to take drugs orally during the planned PK day&#xD;
&#xD;
        NON INCLUSION CRITERIA:&#xD;
&#xD;
          -  Very ill or moribund children unable to take drugs orally or requiring nasogastric&#xD;
             drug intake&#xD;
&#xD;
          -  Severe anaemia (Hb &lt; 6 g/dl),&#xD;
&#xD;
          -  Severe renal impairment (DAIDS grade 3 and above)&#xD;
&#xD;
          -  Severe hepatic impairment (DAIDS grade 3 and above)&#xD;
&#xD;
          -  Children on second line TB drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aurelia Vessière, PhD</last_name>
    <phone>+33 (0)5 57 57 15 35</phone>
    <email>aurelia.vessiere@u-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien Poublan, MPH</last_name>
    <email>julien.poublan@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mulago National Referral Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric Wobudeya, MD</last_name>
      <email>ewobudeya@mujhu.org</email>
    </contact>
    <investigator>
      <last_name>Eric Wobudeya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julier Mwanga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mbarara Regional Hospital</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric Wobudeya, MD</last_name>
      <email>ewobudeya@mujhu.org</email>
    </contact>
    <investigator>
      <last_name>Eric Wobudeya</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliet Manga</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <contact>
      <last_name>Chishala Chabala, MD</last_name>
      <email>cchabala@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chishala Chabala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Mulenga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthur Davison Children Hospital</name>
      <address>
        <city>Ndola</city>
        <country>Zambia</country>
      </address>
    </facility>
    <contact>
      <last_name>Chishala Chabala, MD</last_name>
      <email>cchabala@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chishala Chabala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Mulenga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://www.tb-speed.com</url>
    <description>TB-Speed project official website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Childhood tuberculosis</keyword>
  <keyword>Severe acute malnutrition</keyword>
  <keyword>HIV</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

